Osaic Holdings Inc. Purchases 5,309 Shares of Insulet Corporation $PODD

Osaic Holdings Inc. boosted its position in Insulet Corporation (NASDAQ:PODD) by 152.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,781 shares of the medical instruments supplier’s stock after acquiring an additional 5,309 shares during the period. Osaic Holdings Inc.’s holdings in Insulet were worth $2,709,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Kozak & Associates Inc. bought a new position in shares of Insulet in the 2nd quarter valued at about $32,000. Golden State Wealth Management LLC raised its stake in shares of Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after buying an additional 69 shares during the last quarter. Trust Co. of Toledo NA OH acquired a new position in Insulet in the second quarter valued at approximately $35,000. Osterweis Capital Management Inc. bought a new position in Insulet in the second quarter valued at approximately $51,000. Finally, NewEdge Advisors LLC boosted its stake in Insulet by 44.8% in the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after acquiring an additional 64 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PODD. Wolfe Research increased their price target on Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Evercore ISI began coverage on Insulet in a research note on Tuesday, December 16th. They issued an “outperform” rating and a $370.00 target price on the stock. Rothschild & Co Redburn boosted their target price on Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a research report on Friday, October 3rd. JPMorgan Chase & Co. upped their price target on Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Finally, Canaccord Genuity Group lifted their price objective on shares of Insulet from $432.00 to $450.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $379.00.

Insulet Trading Down 0.1%

NASDAQ PODD opened at $288.63 on Friday. Insulet Corporation has a one year low of $230.05 and a one year high of $354.88. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18. The firm has a market cap of $20.31 billion, a P/E ratio of 83.66, a P/E/G ratio of 2.03 and a beta of 1.37. The stock’s 50-day moving average is $313.67 and its 200-day moving average is $312.84.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The business had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a return on equity of 24.36% and a net margin of 9.76%.Insulet’s revenue for the quarter was up 29.9% compared to the same quarter last year. During the same period in the prior year, the business earned $1.08 EPS. Sell-side analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.